Ineligibility for anticoagulation in patients with atrial fibrillation

Ian del Conde1, Jonathan L Halperin

  • 1The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA.

Insights

Anticoagulation significantly lowers stroke risk in atrial fibrillation but many patients face bleeding risks. This study offers a framework to evaluate anticoagulation

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Atrial fibrillation increases stroke risk.
  • Anticoagulation therapy is effective but limited by bleeding risk in up to 50% of patients.
  • Novel oral anticoagulants offer new treatment options.

Purpose of the Study:

  • To present a framework for assessing anticoagulation's net clinical benefit in atrial fibrillation patients with high bleeding risk.
  • To review data on novel oral anticoagulants (thrombin or factor Xa inhibitors).
  • To discuss the implications of new anticoagulants for therapy eligibility.

Main Methods:

  • Literature review of recent data on novel oral anticoagulants.
  • Framework development for net clinical benefit assessment.
  • Analysis of eligibility criteria for anticoagulation.

Main Results:

  • A framework is proposed to guide clinical decisions.
  • Novel oral anticoagulants may expand anticoagulation options.
  • Distinction between vitamin K antagonist and general anticoagulation eligibility is highlighted.

Conclusions:

  • A structured approach can help manage anticoagulation in high-risk atrial fibrillation patients.
  • Novel oral anticoagulants require careful consideration regarding patient selection and eligibility.
  • Optimizing anticoagulation strategies is crucial for stroke prevention in atrial fibrillation.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...